The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation

Size: px
Start display at page:

Download "The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation"

Transcription

1 & 2010 International Society of Nephrology The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation Edward K. Geissler 1 and Hans J. Schlitt 1 1 Department of Surgery, University Hospital Regensburg, University of Regensburg, Regensburg, Germany Use of the mammalian target of rapamycin (mtor) inhibitor rapamycin in organ transplantation has evolved through different phases over the past two decades. After its discovery in the mid 1970s, antifungal and cytotoxic effects were the first of its properties to be explored, but the most significant advancement was found in its use as an immunosuppressive agent to reduce transplant rejection. This was viewed as an important step forward for immunosuppression, as early studies suggested that rapamycin was less nephrotoxic than calcineurin inhibitors (CNIs). Later, detrimental effects of rapamycin on kidney function were found in some patients. Nonetheless, a fascination with the mtor pathway and its central role in multiple cellular processes has ensued. Among the potential positive clinically relevant effects is rapamycin s capacity to interfere with fibrotic processes that often accompany transplant rejection, and to influence the preferential development of immunological tolerance. A feature of increasing importance is that the mtor pathway is central for vital aspects of tumor development, including angiogenesis and cell growth; rapamycin, therefore, has anticancer activities, which may prove critical in the fight against high cancer rates in transplant recipients. The final chapters defining the value of rapamycin have not been written yet, and indeed remain a work in progress. Only further research will reveal the full potential of rapamycin in organ transplantation. Kidney International (2010) 78, ; doi: /ki ; published online 22 September 2010 KEYWORDS: fibrosis; immunosuppression; malignancy; rapamycin; tolerance Correspondence: Edward K. Geissler, Department of Surgery, University Hospital Regensburg, University of Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg 93053, Germany. edward.geissler@klinik.uni-regensburg.de Received 29 April 2010; revised 24 June 2010; accepted 13 July 2010; published online 22 September 2010 EARLY VERSUS MORE RECENT IMPRESSIONS OF RAPAMYCIN USE IN TRANSPLANTATION Rapamycin was first discovered in the early 1970s from a soil sample taken on Easter Island (Rapa Nui). Based on the molecule s readily apparent antiproliferative effects, it was first tested as an antimicrobial agent and for its cytotoxicity against tumors when used at high concentrations. 1 However, its actual medicinal potential was not revealed until used continuously at low concentrations as an immunosuppressant in organ transplantation. Several pharmacological rapamycin analogs (e.g., sirolimus and CCI-779 (Pfizer, New York, NY, USA), RAD001 (Novartis, Basel, CH, USA), AP23573 (Ariad Pharma, Cambridge, MA, USA)) have been developed, as a result, all of which will simply be hereafter referred to as rapamycin. Regarding its use as an immunosuppressant, it was discovered early that T cells are inhibited by rapamycin as interleukin-2 triggers T-cell proliferation via the mammalian target of rapamycin (mtor) signaling pathway. Expectations became increasingly high that this new immunosuppressive drug would be effective at preventing rejection, although not causing nephrotoxicity associated with calcineurin inhibitors (CNIs) use. Early animal experiments supported this notion, and initial clinical studies also pointed towards reduced nephrotoxicity with rapamycin use. 2 Studies that followed, however, where rapamycin was clinically tested to reduce or eliminate CNI use, particularly in the setting of delayed or chronic renal allograft dysfunction, showed that mtor inhibition can, in some patients, cause proteinuria. 3 The exact effects of mtor inhibition on cells of the kidney are not completely understood, but evidence suggests that tubular cell regeneration is affected, as well as podocytes. 4 Interestingly, podocytes produce vascular endothelial cell growth factor, which is an important factor for maintaining the glomerular filtration barrier; as rapamycin potently inhibits vascular endothelial cell growth factor gene transcription and signaling, 5 proteinuria could be a consequence of its therapeutic use. With proper monitoring and patient selection criteria, proteinuria is avoidable or controllable in most cases with rapamycin use; in more malignant proteinuria situations, rapamycin use needs to be withdrawn. The question of rapamycin effectiveness against rejection also must be considered. In renal transplantation, rapamycin has proved quite effective against kidney rejection when used Kidney International (2010) 78,

2 EK Geissler and HJ Schlitt: Pros of rapamycin use in organ transplantation de novo in combination with CNIs, but to avoid excessive side effects, both substances need to be used at reduced levels. Although an improvement in glomerular filtration rate is reproducible when CNIs are tapered away, 6 the trade-off is that rejection rates may increase. An alternative approach gaining more favor recently is to convert CNI-based immunosuppression to an mtor inhibitor-based regimen at strategic periods within the first year after transplantation. Early clinical data suggest that this option does not increase rejection rates, improves renal function, 7 and provides some protection against chronic allograft nephropathy. 8 To date, however, the issue of whether rapamycin use alone can adequately prevent rejection and improve long-term renal allograft function remains an open question, and is beyond the scope of debate within this concise review. MOLECULAR INTRIGUE Perhaps the most fascinating aspect related to rapamycin is the central significance of the mtor pathway, which it influences. Indeed, the past decade of research on the mtor pathway has revealed its pivotal role in controlling responses to a wide variety of growth factors, cytokines (e.g., interleukin-2), and nutrients. Recent studies indicate that even life span is affected (positively) by mimicking dietary restriction. 9 Through the mtor axis, basic cellular processes such as cell growth and proliferation are regulated, controlling the behavior and development of normal as well as abnormal tissues. In some instances it becomes even more complex because common processes such as angiogenesis are dependent on mtor signaling, affecting both normal tissue repair (e.g., wound healing) and pathological tumor expansion. It is not surprising, therefore, that mtor is highly regulated and integrated with other intracellular signaling pathways. The complexities of this molecular pathway have produced a high degree of molecular intrigue, motivating researchers to investigate the more exact effects of mtor inhibition by rapamycin and other mtor inhibitors. Here, we can only highlight the most critical elements of the mtor signaling pathway (Figure 1). mtor is part of two signaling complexes, mtor complex 1 (mtorc1) and mtorc2. Interestingly, AKT provides signals to mtorc1, but mtorc2 actually regulates AKT through Ser473 phosphorylation. This review focuses on mtorc1, as it is the primary target of rapamycin. Phosphoinositide-dependent kinase-1 phosphorylates AKT at a second site, Thr308, further potentiating AKT activity. A wide variety of growth factors and cytokines can trigger this pathway. Key upstream signaling molecules include phosphoinositide 3-kinase, which converts phosphatidylinositiol-4,5-phosphate to phosphatidylinositiol- 3,4,5-phosphate and recruits phosphoinositide-dependent kinase-1 to AKT. Another important molecule is PTEN (phosphatase and tensin homolog deleted on chromosome 10), which is a tumor suppressor that reverses the phosphatidylinositiol-4,5-phosphate-to-phosphatidylinositiol-3,4,5-phosphate reaction, thus reducing AKT activity. Indeed, AKT has a critical role by mediating mtorc1 activation via inhibition of Nutrients mtor mtorc2 Rapamycin Growth factors: e.g., IL-2, VEGF S6K1 Transcription P13K PDK1 AKT TSC1/2 Rheb mtor mtorc1 PTEN 4E-BP1 eif-4e Translation IKKβ PC-1 Other signaling pathways (e.g., MAPK) Cell growth and metabolism Figure 1 mtorc1 pathway basics. Abbreviations: eif-4e, eukaryotic initiation factor 4E; IKKb, inhibitory kb kinase-b; IL-2, interleukin-2; MAPK, mitogen-activated protein kinase; mtor, mammalian target of rapamycin; mtorc, mtor complex; PC-1, polycystin-1; PDK1, phosphoinositide-dependent kinase-1; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog deleted on chromosome 10; Rheb, Ras homolog enriched in brain; S6K1, S6 kinase 1; TSC, tuberous sclerosis complex; VEGF, vascular endothelial cell growth factor; 4E-BP1, eif-4e-binding protein-1. the tumor suppressors, hamartin tuberous sclerosis complex (TSC)1) and tuberin (TSC2). The TSC1/2 complex inactivates Rheb (Ras homolog enriched in brain), thereby inhibiting mtorc1 activation. The primary downstream effectors of mtorc1 are S6 kinase 1 and eukaryotic initiation factor 4E-binding protein-1, which are important regulators of mrna translation. Interestingly, to apparently protect against overactivation of mtorc1, active S6 kinase 1 negatively feeds back to inhibit AKT, and thus activation of mtorc1. The mtor pathway is tangentially influenced in many ways. For instance, inhibitory kb kinase-b, a kinase downstream of tumor necrosis factor-a, integrates with mtorc1 by inhibiting TSC1/2, molecularly linking inflammation and cell proliferation. 10 The mitogen-activated protein kinase cascade is also linked to mtor, as inhibition of one pathway affects the activation of the other. Additionally, mtor, because of its effects on cell growth, is intimately involved in energy metabolism. For instance, mtorc1 activity is regulated by sensing cellular adenosine triphosphate levels (via AMP-activated protein kinase and TSC1/2) and by sensing amino acids. 11 Even lipid metabolism is influenced by 1076 Kidney International (2010) 78,

3 EK Geissler and HJ Schlitt: Pros of rapamycin use in organ transplantation mtorc1, positively affecting peroxisome proliferator-activated receptor-g, which has an important role in adipogenesis and lipid accumulation. 12 Therefore, mtor s central intracellular signaling position in essential cell processes make it an attractive therapeutic target for conditions where it is desirable to reduce cell growth and proliferation (e.g., T cells immune suppression, neoplastic cells oncology, endothelial and smooth muscle cells vasculopathy). DISCOVERY OF ANTITUMOR EFFECTS Besides the well-known immunosuppressive properties of rapamycin, there is a rapidly expanding literature base on its anticancer effects. Although early toxicology studies showed some modest effects on tumors, the concentrations of rapamycinusedintheseexperimentswerehighandcarried significant toxicity. 1 Enthusiasm for rapamycin use as a pure oncologic agent faded until early in the present decade. A better understanding of the mtor signaling pathway brought new hypotheses as to how rapamycin could be used more effectively against cancer. One breakthrough came in 2002 when Guba et al. 5 discovered in mice that rapamycin potently inhibits tumor angiogenesis, and thus tumor growth, at relatively low, sustainable, concentrations that are compatible with long-term immunosuppression in transplant recipients. Evidence suggested that the antiangiogenic effect was related to inhibition of vascular endothelial cell growth factor production and endothelial cell responses to vascular endothelial cell growth factor, which are both dependent on the mtor pathway. This key finding was later confirmed by others, and tumors highly dependent on angiogenesis have since shown positive responses to rapamycin treatment. 13,14 A natural question in the context of organ transplantation is whether rapamycin could cause a tumor to regress in immunosuppressed patients. Indeed, it has been shown that rapamycin can prevent allograft rejection in mice through its immunosuppressive effects, while at the same time inhibiting tumor growth. 15 At least in the situation of Kaposi s sarcoma in renal transplant recipients, this idea has shown clinical results. 13 These examples are an extraordinary demonstration of the multiple effects of rapamycin, and they stress the central importance of this pathway for essential cellular processes. The anticancer effects of rapamycin are not limited to angiogenesis. Tumor cells are often directly dependent on the mtor pathway because of their need to use its proliferationpromoting mechanisms and because gene mutations within the pathway can constitutively activate mtor. There are many examples that illustrate this latter point. For example, PTEN and TSC1/2 can be oncogenic through mutations that result in a release of their inhibitory effects on mtorc1; e.g., tuberous sclerosis is a specific hyperproliferative condition that results from mutations in the tuberous sclerosis suppressor complex. Overexpression of the receptor tyrosine kinase human epidermal growth factor receptor 2 in malignancies such as breast and gastric cancer is another example of promoting pathological signaling through the AKT/mTORC1 axis. Polycystic kidney disease is a condition where mutations in polycystin-1 have very recently been shown to cause a lack of tethering of TSC2 to the cell membrane, decreasing the ability of TSC2 to repress mtorc1. 16 These and other mtorc1 pathway-promoting gene mutations make mtor an attractive target for antitumor therapy. Recent studies also suggest that rapamycin has even broader ranging effects that influence the growth and development of tumors. For instance, rapamycin treatment markedly reduces spontaneous de novo intestinal tumor formation in APC min/ þ mice, with a near complete correction in the expression of otherwise upregulated oncogenic Na þ and K þ ion channels; 17 the mechanism for the normalization of oncogenic ion channels is unknown. Rapamycin can also strongly affect the pattern of ultraviolet-signature p53 mutations, which are thought to be important in skin cancer development. 18 Therefore, there is even evidence that mtor influences processes that affect DNA damage repair. With more research and a better understanding of the mtor pathway, the spectrum of rapamycin effects that may impact tumor growth will likely continue to expand. Finally, we cannot leave this discussion without addressing the potential impact that rapamycin has on immunity against tumor cells and viruses. An intuitive reaction to this point is that rapamycin inhibits the immune system in general and therefore must diminish immunity against invasive neoplasms. Although this is a reasonable argument, the conclusion appears premature and full of complexities. In favor of this hypothesis are two main factors, the well-known general suppressive effect that rapamycin has on T-cell proliferation, and its recently discovered promotion of T-regulatory cell development. 19 It can be reasonably speculated that T-regulatory cells could act locally within a tumor, or systemically towards a virus, to protect against invading immune cells; much the same idea as the protection against rejection that is expected with T-regulatory cells in a patient with a tolerant organ allograft. Although it is concerning that rapamycin treatment could promote immunological tolerance to a tumor entity or virus, there is recent data that takes a completely opposite perspective. Rao et al. 20 have recently reported that mtor inhibition with rapamycin inhibits T- bet and promotes eomesodermin expression, which is associated with an enhanced memory phenotype in CD8 þ cells; rapamycin-treated CD8 þ cells showed impressive antitumor activity in vivo. Data also suggest that rapamycin-exposed CD8 þ cells could work favorably against BK virus, 21 cytomegalovirus, 22 or other viruses 23 associated with infectious and neoplastic diseases in transplant recipients (e.g., Epstein Barr virus in posttransplant lymphoproliferative disease; herpesvirus in Kaposi s sarcoma). Indeed, a recent organ transplantation guideline publication suggests that there may be a lower incidence of cytomegalovirus infections when using mtor inhibitors. 24 It has to be added, however, that conflicting data and much controversy surrounds this topic, so further studies will be critical in determining the balance of effects rapamycin has on the development of malignancies and viral infections. Kidney International (2010) 78,

4 EK Geissler and HJ Schlitt: Pros of rapamycin use in organ transplantation TOLERANCE-INDUCTION POTENTIAL There is much debate about which immunosuppressive agents and regimens may possess the most favorable properties for tolerance induction in organ transplantation. Early experimental data indicate that CNI use, through blocking T-cell activation, may hinder the development of immunological tolerance. 25 In contrast, allowing T-cell activation, but not proliferation, by using rapamycin could potentially promote tolerance. Moreover, recent publications indicate that as mtorc1 is essential for the development of conventional effector T cells, blocking mtorc1 with rapamycin likely favours T-regulatory cell expansion. 26 Indeed, expanding T-regulatory cells either through drug therapy or ex vivo cell therapy is being considered in novel transplant tolerance-induction strategies. Rapamycin may also indirectly promote T-cell anergy and regulation by inhibiting the maturation of dendritic cells. 27 However, the immune response depending on mtor is as complex as that when considering its influence on tumor formation. For instance, it has been shown that molecules involved in the innate immune response (e.g., toll-like receptor 4) can actually inhibit the production of inflammatory cytokines through mtor, thus predicting that mtor inhibition could be proinflammatory. 28 Therefore, the timing of therapeutic rapamycin application may be critical in determining its potential in inducing immunological tolerance. These considerations notwithstanding, mtor has a central, albeit complex, role in directing the immune response. CONTROL OF FIBROTIC PROCESSES Preventing development of interstitial renal fibrosis remains an unsolved problem following organ transplantation. Although we have learned how to control early and late acute rejection reactions against allografts, chronic pathological processes such as fibrosis have not proven to be controllable. When considering renal fibrosis, transforming growth factor-b is a well-known primary mediator through induction of fibroblast proliferation and myofibroblast transition. Although smad-2 and -3 are the most commonly known substrates of the transforming growth factor-b receptor, recent evidence also suggests that transforming growth factor-b signals via other pathways, including the AKT/mTORC1 axis. 29 Indeed, blocking mtorc1 with rapamycin has been recently shown to reduce renal interstitial fibrosis in an obstructive nephropathy rodent model by diminishing the number of interstitial fibroblasts and myofibroblasts. 30 The question remains, however, whether rapamycin can reduce fibrosis in transplant recipients. Data have been analyzed from different trials where patients on CNIs were later converted to rapamycin, but the results are conflicting. Pontrelli et al. 31 have reported that rapamycin can substantially reduce interstitial fibrosis in renal transplant recipients after a chronic allograft nephropathy diagnosis, whereas Servais et al. 32 didnotfindasignificantreductionin fibrosisafter1yearwhenpatientswereconvertedfromcnisto rapamycin 12 weeks after renal transplantation. A number of factors can explain the results of the latter study, as the negative effects of CNIs can occur very early (before randomization) and the readout was for a short period, possibly not allowing for detection of a difference within the observed time frame. Nonetheless, more trials testing this hypothesis will clearly need to be performed to determine whether fibrosis can be influenced by rapamycin following renal transplantation. We should add to this discussion that hepatic fibrosis associated with liver disease may also be targetable with rapamycin treatment, as a recent experimental study in rats has demonstrated. 33 Interestingly, multiple profibrinogenic pathways are operable within liver tissue, suggesting that the mechanism of rapamycin inhibition of fibrosis in the liver is different than that which takes place in the kidney. PITFALLS OF RAPAMYCIN USE IN TRANSPLANTATION Although this review concentrates on the positive aspects of rapamycin use in transplantation, it is important to include some discussion of the pitfalls encountered with the use of this substance or its derivatives. The most common problems are associated with side effects that can decrease the quality of life for some transplant recipients. In particular, oral ulcers, skin lesions (e.g., acne) and various forms of edema can present distressing problems for patients. In these cases, dose reductions can be helpful, along with specific counteractive treatments, but the problems may continue to persist and eventually result in rapamycin discontinuation. Furthermore, other serious side effects include wound-healing problems after surgery, delayed graft function, anemia, pneumonitis, and the problem described earlier with proteinuria in some patients. These types of side effects have sometimes resulted in elevated dropout rates in clinical studies. Although a legitimate argument can be made that physicians prematurely switch patients off mtor inhibitors before making enough efforts to manage the side effects, it is also fair to make the argument that treatment with mtor inhibitors requires substantial medical management. Therefore, assessment of the risk/benefit profile of rapamycin use in individual renal transplant recipients has become a central, and decisive, issue. CLINICAL PERSPECTIVES When trying to calculate the future of rapamycin use in organ transplantation, there are many factors that have to go into the equation. Factors of particular importance that have to be considered are the development of malignancy and chronic fibrosis, both of which are critical problems facing transplantation medicine. Based on our present knowledge of the mtor pathway, including experimental and clinical data that are presently available, an argument can be made for rapamycin treatment as a means to diminish these serious and otherwise untreatable post-transplant complications. Moreover, of the immunosuppressants currently available for transplantation, rapamycin has shown the highest potential to support the development of immunological tolerance in experimental models, especially those that espouse tolerance through the induction of anergy and 1078 Kidney International (2010) 78,

5 EK Geissler and HJ Schlitt: Pros of rapamycin use in organ transplantation T-regulatory cells. This is not an insignificant consideration, given that the induction of at least some level of stable immunological tolerance remains the holy grail of transplantation medicine. If future clinical trials can definitively show that any of these potential positive attributes are veritable, mtor inhibitors could gain a more broader base of acceptance in organ transplantation. The value of rapamycin in the situation where a malignancy occurs, or has a high probability of occurrence, in transplant recipients is especially promising. In this respect, one important ongoing multicentre clinical study is testing whether rapamycin treatment can reduce hepatocellular carcinoma-free survival in liver transplant recipients with a pretransplant hepatocellular carcinoma. 34 Demonstration of a clear long-term benefit from this and other ongoing or planned clinical studies will give motivation for transplant physicians to better manage the side effects associated with rapamycin use, rather than prematurely switching to other immunosuppressants that possess their own undesirable side effect profiles. In the meantime, intrigue regarding the central role mtor has in multiple cellular processes will continue to shed new light onto the potential therapeutic usefulness of mtor inhibitors in organ transplantation. What is known so far is that rapamycin is a drug with potent immunosuppressive, antiproliferative, and antitumor effects, indicating that this substance influences a wide range of cell types and cellular processes. The level of this complexity is shown by rapamycin s ability to treat multiple conditions simultaneously, as demonstrated by its combined immunosuppressive and anticancer action in transplant patients with a malignancy. The question that still needs to be answered is whether the balance of positive effects outweighs the side effects that often accompany treatment. Only further experimental and clinical studies can answer this question. DISCLOSURE All the authors declared no competing interests. ACKNOWLEDGMENTS Source of support: RISET: A European Union FP6 program aimed at resetting the immune system for the establishment of tolerance. REFERENCES 1. Eng CP, Sehgal SN, Vézina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot 1984; 37: Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: Ruiz JC, Campistol JM, Sanchez-Fructuoso A et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006; 21: Torras J, Herrero-Fresneda I, Gulias O et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant 2009; 24: Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. JAmSoc Nephrol 2004; 15: Rostaing L, Kamar N. mtor inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010; 23: Harrison DE, Strong R, Sharp ZD et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: Lee DF, Kuo HP, Chen CT et al. IKKb suppression of TSC1 links inflammation and tumor angiogenesis via the mtor pathway. Cell 2007; 130: Nicklin P, Bergman P, Zhang B et al. Bidirectional transport of amino acids regulates mtor and autophagy. Cell 2009; 136: Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptorg activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004; 53: Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi s sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. NEnglJMed2007; 356: Koehl G, Andrassy J, Guba M et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: Dere R, Wilson PD, Sandford RN et al. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mtor. PLoS One 2010; 5: e Koehl GE, Spitzner M, Ousingsawat J et al. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC Min/+ mice. Oncogene 2010; 29: de Gruijl FR, Koehl GE, Voskamp P et al. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer 2009; 127: Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: Rao RR, Li Q, Odunsi K et al. The mtor kinase determines effector versus memory CD8 + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010; 32: Egli A, Köhli S, Dickenmann M et al. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation 2009; 88: Mueller NJ. New immunosuppressive strategies and the risk of infection. Transpl Infect Dis 2008; 10: Araki K, Youngblood B, Ahmed R. The role of mtor in memory CD8 + T-cell differentiation. Immunol Rev 2010; 235: Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: Li Y, Zheng XX, Li XC et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4 + Foxp3 + cells. J Exp Med 2008; 205: Turnquist HR, Raimondi G, Zahorchak AF et al. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4 + T cells, but enrich for antigen-specific Foxp3 + T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: Weichhart T, Costantino G, Poglitsch M et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29: Rahimi RA, Andrianifahanana M, Wilkes MC et al. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-b. Cancer Res 2009; 69: Wang S, Wilkes MC, Leof EB et al. Noncanonical TGF-b pathways, mtorc1 and Ab1, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010; 298: F142 F Pontrelli P, Rossini M, Infante B et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85: Servais A, Meas-Yedid V, Toupance O et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: Bridle KR, Popa C, Morgan ML et al. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl 2009; 15: Schnitzbauer AA, Zuelke C, Graeb C et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mtor-inhibitorfree immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190. Kidney International (2010) 78,

A particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy se

A particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy se A particular set of insults induces apoptosis (part 1), which, if inhibited, can switch to autophagy. At least in some cellular settings, autophagy serves as a defence mechanism that prevents or retards

More information

The PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction

The PI3K/AKT axis. Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia. Introduction The PI3K/AKT axis Dr. Lucio Crinò Medical Oncology Division Azienda Ospedaliera-Perugia Introduction Phosphoinositide 3-kinase (PI3K) pathway are a family of lipid kinases discovered in 1980s. They have

More information

mtor inhibitors lights and shadows Giuseppe Grandaliano, Foggia, Italy Chairs: Turgay Arinsoy, Ankara, Turkey Josep M. Grinyo, Barcelona, Spain

mtor inhibitors lights and shadows Giuseppe Grandaliano, Foggia, Italy Chairs: Turgay Arinsoy, Ankara, Turkey Josep M. Grinyo, Barcelona, Spain mtor inhibitors lights and shadows Giuseppe Grandaliano, Foggia, Italy Chairs: Turgay Arinsoy, Ankara, Turkey Josep M. Grinyo, Barcelona, Spain Prof. Giuseppe Grandaliano Nephrology Department Faculty

More information

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University

More information

Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation

Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Trends Fritz in Transplant. Diekmann: 2011;5:139-43 Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation

More information

Potential Catalysts in Therapeutics

Potential Catalysts in Therapeutics LIVER TRANSPLANTATION 20:S22 S31, 2014 SUPPLEMENT Potential Catalysts in Therapeutics Bruce A. Luxon Division of Gastroenterology-Hepatology, University of Iowa, Iowa City, IA Received July 23, 2014; accepted

More information

OBJECTIVES. Phases of Transplantation and Immunosuppression

OBJECTIVES. Phases of Transplantation and Immunosuppression Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and

More information

EPS meeting. Post-transplant EPS. Naarden, The Netherlands February 4 th 2010

EPS meeting. Post-transplant EPS. Naarden, The Netherlands February 4 th 2010 Naarden, The Netherlands February 4 th 2010 EPS meeting Post-transplant EPS Guido Garosi U.O.C. Nefrologia, Dialisi e Trapianto Azienda Ospedaliera Universitaria Senese Siena, Italy is post-transplant

More information

Pleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble

Pleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Pleiotropic effects of mtor inhibitors : cardiovascular and cancer Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Tehran August 2016 Why this topic? Since last year very little news in the immunosuppressive

More information

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells 1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:

More information

Tumor Immunology: A Primer

Tumor Immunology: A Primer Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Why Do We Need New Immunosuppressive Agents

Why Do We Need New Immunosuppressive Agents Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for

More information

FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1

FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1 1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory

More information

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction

More information

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80% SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information

Diabetes Mellitus and Breast Cancer

Diabetes Mellitus and Breast Cancer Masur K, Thévenod F, Zänker KS (eds): Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel, Karger, 2008, vol 19, pp 97 113 Diabetes Mellitus and Breast Cancer Ido Wolf

More information

Liver Transplant Immunosuppression

Liver Transplant Immunosuppression Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be

More information

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent

More information

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis. Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)

More information

tients with insufficient TOR inhibitor therapy that are at risk for rejection.

tients with insufficient TOR inhibitor therapy that are at risk for rejection. Kidney International, Vol. 68 (05), pp. 2593 2598 Biochemical monitoring of mtor inhibitor based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy

More information

European Risk Management Plan. Measures impairment. Retreatment after Discontinuation

European Risk Management Plan. Measures impairment. Retreatment after Discontinuation European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin

More information

Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone

Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone 1 Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone Cancer is a disease caused by out of control division of abnormal cells within a

More information

Tolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS

Tolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS 1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails

More information

Conversion from calcineurin inhibitors to sirolimus in renal transplant patients

Conversion from calcineurin inhibitors to sirolimus in renal transplant patients ORIGINAL ARTICLE Port J Nephrol Hypert 2008; 22(1): 43-48 Conversion from calcineurin inhibitors to sirolimus in renal transplant patients Unidade de Transplantação Renal. Serviço de Nefrologia. Hospital

More information

Emerging Drug List EVEROLIMUS

Emerging Drug List EVEROLIMUS Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine

More information

Tolerance 2. Regulatory T cells; why tolerance fails. FOCiS. Lecture outline. Regulatory T cells. Regulatory T cells: functions and clinical relevance

Tolerance 2. Regulatory T cells; why tolerance fails. FOCiS. Lecture outline. Regulatory T cells. Regulatory T cells: functions and clinical relevance 1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails

More information

Backgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?

Backgrounder. 1. What are targeted therapies? 2. How do targeted therapies work? Backgrounder TARGETED THERAPIES FOR CANCER 1. What are targeted therapies? 2. How do targeted therapies work? 3. What are some of the different types of targeted therapy? 4. What are the potential benefits

More information

Basis and Clinical Applications of Interferon

Basis and Clinical Applications of Interferon Interferon Therapy Basis and Clinical Applications of Interferon JMAJ 47(1): 7 12, 2004 Jiro IMANISHI Professor, Kyoto Prefectural University of Medicine Abstract: Interferon (IFN) is an antiviral substance

More information

Immunopathology of T cell mediated rejection

Immunopathology of T cell mediated rejection Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant

More information

renoprotection therapy goals 208, 209

renoprotection therapy goals 208, 209 Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization

More information

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC

More information

IMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar

IMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences

More information

Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate

Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate Case Reports in Transplantation, Article ID 190516, 4 pages http://dx.doi.org/10.1155/2014/190516 Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration

More information

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. Mechanisms of Immune Tolerance ACTIVATION (immunity) SUPPRESSION (tolerance)

More information

Mechanisms of Immune Tolerance

Mechanisms of Immune Tolerance Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. ACTIVATION (immunity) SUPPRESSION (tolerance) Autoimmunity Immunodeficiency

More information

Chapter 7 Conclusions

Chapter 7 Conclusions VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy

More information

Date: 23 June Context and policy issues:

Date: 23 June Context and policy issues: Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review

More information

Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation

Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation Trends in Transplantation Transplant. 2012;6:28-33 Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation Hallvard Holdaas Department

More information

CLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12

CLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12 Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline 1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for

More information

T Cell Activation, Costimulation and Regulation

T Cell Activation, Costimulation and Regulation 1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family

More information

The g c Family of Cytokines Prof. Warren J. Leonard M.D.

The g c Family of Cytokines Prof. Warren J. Leonard M.D. The Family of Cytokines Chief, Laboratory of Molecular Immunology Director, Immunology Center National Heart, Lung, and Blood Institute National Institutes of Health Department of Health and Human Services

More information

T cell maturation. T-cell Maturation. What allows T cell maturation?

T cell maturation. T-cell Maturation. What allows T cell maturation? T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry

More information

Targeted and immunotherapy in RCC

Targeted and immunotherapy in RCC Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted

More information

Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases

Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases 54 Review Article Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases Toshio Tanaka 1, 2), Masashi Narazaki 3), Kazuya Masuda 4) and Tadamitsu Kishimoto 4, ) 1) Department of

More information

Immunological Tolerance

Immunological Tolerance Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for

More information

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H. Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for

More information

Viruses and cancer: Should we be more afraid?

Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? During the past 30 years it has become exceedingly clear that several viruses play significant roles in the development

More information

Crosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea

Crosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia

More information

RAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.

RAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. ۱ RAS Genes The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. Oncogenic ras genes in human cells include H ras, N ras,

More information

SEVENTH EDITION CHAPTER

SEVENTH EDITION CHAPTER Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some

More information

Belatacept: An Update of Ongoing Clinical Trials

Belatacept: An Update of Ongoing Clinical Trials Belatacept: An Update of Ongoing Clinical Trials Michael D. Rizzari, MD University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin Abstract Belatacept is a fusion protein

More information

CHAPTER I INTRODUCTION. Nowadays chronic kidney disease (CKD) becomes one. of the most common diseases found in the population.

CHAPTER I INTRODUCTION. Nowadays chronic kidney disease (CKD) becomes one. of the most common diseases found in the population. CHAPTER I INTRODUCTION I.1 Background Nowadays chronic kidney disease (CKD) becomes one of the most common diseases found in the population. Based on community survey that is held by PERNEFRI (Perhimpunan

More information

Immuno-Oncology: Perspectives on Current Therapies & Future Developments

Immuno-Oncology: Perspectives on Current Therapies & Future Developments Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/immuno-oncology-perspectives-currenttherapies-future-developments/9502/

More information

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated

More information

Overview of New Approaches to Immunosuppression in Renal Transplantation

Overview of New Approaches to Immunosuppression in Renal Transplantation Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute

More information

EGFR Antibody. Necitumumab, LY , IMC-11F8. Drug Discovery Platform: Cancer Cell Signaling

EGFR Antibody. Necitumumab, LY , IMC-11F8. Drug Discovery Platform: Cancer Cell Signaling EGFR Antibody Necitumumab, LY3012211, IMC-11F8 Derived from Yarden Y and Shilo BZ 1 ; Schneider MR and Wolf E. 2 Drug Discovery Platform: Cancer Cell Signaling A Single-Arm, Multicenter, Open-Label, Phase

More information

Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF

Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases Abul K. Abbas UCSF Balancing lymphocyte activation and control Activation Effector T cells Tolerance Regulatory T cells

More information

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD

More information

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Immune surveillance hypothesis (Macfarlane Burnet, 1950s) TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,

More information

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,

More information

7.012 Problem Set 6 Solutions

7.012 Problem Set 6 Solutions Name Section 7.012 Problem Set 6 Solutions Question 1 The viral family Orthomyxoviridae contains the influenza A, B and C viruses. These viruses have a (-)ss RNA genome surrounded by a capsid composed

More information

Analysis on the mechanism of reduced nephron number and the pathological progression of chronic renal failure in Astrin deficient rats

Analysis on the mechanism of reduced nephron number and the pathological progression of chronic renal failure in Astrin deficient rats Analysis on the mechanism of reduced nephron number and the pathological progression of chronic renal failure in Astrin deficient rats Summary of Doctoral Thesis Hidenori Yasuda Graduate School of Veterinary

More information

Convergent and Divergent Mechanisms in Aging and Cancer

Convergent and Divergent Mechanisms in Aging and Cancer Convergent and Divergent Mechanisms in Aging and Cancer Mariana S. De Lorenzo, PhD Department of Cell Biology & Molecular Medicine delorems@umdnj.edu LEARNING OBJECTIVES 1. To identify convergent and divergent

More information

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard

More information

Radiation therapy Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Chemotherapy Chemotherapy is a cancer

More information

Darwinian selection and Newtonian physics wrapped up in systems biology

Darwinian selection and Newtonian physics wrapped up in systems biology Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid

More information

Case Presentation Turki Al-Hussain, MD

Case Presentation Turki Al-Hussain, MD Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory

More information

CMV INFECTION IN KIDNEY TRANSPLANTATION

CMV INFECTION IN KIDNEY TRANSPLANTATION CMV INFECTION IN KIDNEY TRANSPLANTATION PIERRE MERVILLE CHU BORDEAUX - UNIVERSITÉ BORDEAUX SEGALEN UMR-CNRS 5164 SUMMARY: 1.Epidemiology in kidney transplantation 2.T T cell response: αβ and γδ lymphocytes

More information

Immunomodulator y effects of CMV disease

Immunomodulator y effects of CMV disease Immunomodulator y effects of CMV disease Oriol Manuel MD Service of Infectious Diseases and Transplantation Center University Hospital of Lausanne Switzerland Outline The transplant troll The indirect

More information

Transplant Hepatology

Transplant Hepatology Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified

More information

Immune Regulation and Tolerance

Immune Regulation and Tolerance Immune Regulation and Tolerance Immunoregulation: A balance between activation and suppression of effector cells to achieve an efficient immune response without damaging the host. Activation (immunity)

More information

Disorders of Cell Growth & Neoplasia

Disorders of Cell Growth & Neoplasia General Pathology VPM 152 Disorders of Cell Growth & Neoplasia Lecture 3 Rate of growth, local invasion, and metastasis. Molecular basis of cancer (normal cell-cycle and cellular proliferation). Enrique

More information

Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors

Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors ORIGINAL ARTICLE Korean J Intern Med 216;31:552-559 http://dx.doi.org/1.394/kjim.214.366 Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure

More information

1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples. Major Principles:

1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples. Major Principles: Carcinogenesis 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples Carcinogenesis Major Principles: 1. Nonlethal genetic damage is central to

More information

Kidneytransplant pathologyrelatedto immunosuppressiveagents

Kidneytransplant pathologyrelatedto immunosuppressiveagents Kidneytransplant pathologyrelatedto immunosuppressiveagents Helmut Hopfer Pathologie Women, 53 years old. 16 months after kidney transplantation for diabetic nephropathy. Metabolicsyndromeandcoronaryheartdisease.

More information

MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy

MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Ondrej Viklicky Department of Nephrology Transplant

More information

Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients

Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients Original Research Article Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients Surendran Sujit 1*, N. Gopalakrishnan 2 1 Assistant Professor, 2 Professor and Head Department

More information

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway AWARD NUMBER: W81XWH-12-1-0560 TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway PRINCIPAL INVESTIGATOR: Andrew S. Kraft, MD CONTRACTING ORGANIZATION:

More information

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve

More information

Intron A. Intron A (interferon alfa-2b) Description

Intron A. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Page: 1 of 6 Last Review Date: June 19, 2015 Intron A Description Intron A (interferon

More information

Recognition and Treatment of Chronic Allograft Dysfunction

Recognition and Treatment of Chronic Allograft Dysfunction Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs

More information

Novel therapeutic approach for kidney fibrosis

Novel therapeutic approach for kidney fibrosis University of Sydney Novel therapeutic approach for kidney fibrosis DAVID HARRIS 30/09/17 Westmead Hospital Cadnapaphornchai CJASN 2014;9:889 Liraglutide: Renal Outcomes Mann JFE et al. N Engl J Med 2017;377:839-848

More information

Page 32 AP Biology: 2013 Exam Review CONCEPT 6 REGULATION

Page 32 AP Biology: 2013 Exam Review CONCEPT 6 REGULATION Page 32 AP Biology: 2013 Exam Review CONCEPT 6 REGULATION 1. Feedback a. Negative feedback mechanisms maintain dynamic homeostasis for a particular condition (variable) by regulating physiological processes,

More information

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was

More information

EBV infection B cells and lymphomagenesis. Sridhar Chaganti

EBV infection B cells and lymphomagenesis. Sridhar Chaganti EBV infection B cells and lymphomagenesis Sridhar Chaganti How EBV infects B-cells How viral genes influence the infected B cell Differences and similarities between in vitro and in vivo infection How

More information

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

Biol403 MAP kinase signalling

Biol403 MAP kinase signalling Biol403 MAP kinase signalling The mitogen activated protein kinase (MAPK) pathway is a signalling cascade activated by a diverse range of effectors. The cascade regulates many cellular activities including

More information

VIRUSES AND CANCER Michael Lea

VIRUSES AND CANCER Michael Lea VIRUSES AND CANCER 2010 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review

More information

number Done by Corrected by Doctor Maha Shomaf

number Done by Corrected by Doctor Maha Shomaf number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads

More information

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3

More information

DAWNING OF THE AGE OF ANGIOGENESIS

DAWNING OF THE AGE OF ANGIOGENESIS DAWNING OF THE AGE OF ANGIOGENESIS Bob Leibowitz, M.D. DIPLOMATE AMERICAN BOARDS OF INTERNAL MEDICINE AND SUBSPECIALTIES OF MEDICAL ONCOLOGY AND HEMATOLOGY December 1997 April 2004 (Revised) Angiogenesis

More information

Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture:

Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture: Transformation of Normal HMECs (Human Mammary Epithelial Cells) into Metastatic Breast Cancer Cells: Introduction - The Broad Picture: Spandana Baruah December, 2016 Cancer is defined as: «A disease caused

More information

Signaling. Dr. Sujata Persad Katz Group Centre for Pharmacy & Health research

Signaling. Dr. Sujata Persad Katz Group Centre for Pharmacy & Health research Signaling Dr. Sujata Persad 3-020 Katz Group Centre for Pharmacy & Health research E-mail:sujata.persad@ualberta.ca 1 Growth Factor Receptors and Other Signaling Pathways What we will cover today: How

More information

Renal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic

Renal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic Renal Pathology- Transplantation Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Kidney has a limited number of tissue reactions by which the kidney

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors

More information